A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). uri icon

Overview

publication date

  • July 1, 2018

Identity

PubMed Central ID

  • PMC6888018

Scopus Document Identifier

  • 85051474347

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdx801

PubMed ID

  • 29300804

Additional Document Info

volume

  • 29

issue

  • 7